Bionano Really Is One-of-a-Kind Bionano Genom
Post# of 99
(Total Views: 148)
Posted On: 09/10/2025 7:57:30 PM
Bionano Really Is One-of-a-Kind
Bionano Genomics is the only company named in a dedicated NIH contract for structural-variation mapping reagents and instruments, a federal endorsement no competitor holds. Bionano occupies a singular niche in genomics and cytogenetics thanks to its proprietary optical genome mapping platform. No other vendor combines nanochannel-based OGM, a sole-source NIH contract, and seamless integration with Illumina sequencing and Revvity workflows.
None of the alternative collaborations, whether it’s PacBio + Illumina + Arima, Oxford Nanopore + Illumina + DNAnexus, Thermo Fisher + QIAGEN + SOPHiA, or Roche + Covaris + QIAGEN, has received the type of sole-source award from the NIH that Bionano secured for its optical genome mapping platform.
NIH’s sole-source contract explicitly names Bionano as the only vendor for detecting large structural variants under simplified acquisition rules. That arrangement signals a formal federal endorsement of optical genome mapping in clinical research and diagnostic workflows, something no other technology partnership currently enjoys.
While many vendors and partnerships are heavily used in NIH-backed studies, Bionano remains unique in holding a dedicated NIH instrument and reagent contract. It’s a clear stamp of approval for structural-variation mapping that sets the Bionano + Illumina + Revvity triumvirate even further ahead in integrated genomics and cytogenetics.
Bionano Genomics is the only company named in a dedicated NIH contract for structural-variation mapping reagents and instruments, a federal endorsement no competitor holds. Bionano occupies a singular niche in genomics and cytogenetics thanks to its proprietary optical genome mapping platform. No other vendor combines nanochannel-based OGM, a sole-source NIH contract, and seamless integration with Illumina sequencing and Revvity workflows.
None of the alternative collaborations, whether it’s PacBio + Illumina + Arima, Oxford Nanopore + Illumina + DNAnexus, Thermo Fisher + QIAGEN + SOPHiA, or Roche + Covaris + QIAGEN, has received the type of sole-source award from the NIH that Bionano secured for its optical genome mapping platform.
NIH’s sole-source contract explicitly names Bionano as the only vendor for detecting large structural variants under simplified acquisition rules. That arrangement signals a formal federal endorsement of optical genome mapping in clinical research and diagnostic workflows, something no other technology partnership currently enjoys.
While many vendors and partnerships are heavily used in NIH-backed studies, Bionano remains unique in holding a dedicated NIH instrument and reagent contract. It’s a clear stamp of approval for structural-variation mapping that sets the Bionano + Illumina + Revvity triumvirate even further ahead in integrated genomics and cytogenetics.
(0)
(0)